Kingworld Medicines Group Ltd. (1110) AI Stock Analysis

Kingworld Medicines Group Ltd.

(HKEX:1110)

Select Model

Rating:56Neutral

Price Target:HKD 0.39▲(4.27% Upside)

Action:reiterated

Date:10/15/26

Moderate financial performance and weak technical signals are the primary drags, partially mitigated by attractive dividend yield.

Positive Factors

Stable Gross MarginRecent gross margin staying in the mid-to-high 20% range indicates the underlying product distribution economics have remained comparatively resilient. This provides a base for recovery if sales stabilize, although it has not prevented pressure on operating profitability.

Negative Factors

Revenue DeclineRevenue weakening in consecutive years signals that sales momentum has deteriorated after strong growth during 2021–2023. Unless demand or channel volumes recover, the smaller revenue base can constrain operating leverage, investment capacity, and the company’s ability to rebuild earnings.

Kingworld Medicines Group Ltd. (1110) vs. iShares MSCI Hong Kong ETF (EWH)

Market Cap: HKD 221.18M
Dividend Yield: 8.45%
Average Volume (3M): 2.01M
Price to Earnings (P/E): 16.8
Beta (1Y): 0.18
Revenue Growth: -13.82%
EPS Growth: 112.24%
Country: Hong Kong
Employees: 711
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Distribution

Kingworld Medicines Group Ltd. Business Overview & Revenue Model

Company Description

Kingworld Medicines Group Limited functions as an investment holding company primarily engaged in the distribution of imported, branded pharmaceutical and healthcare items. The company also supplies a range of medical products, health goods, and gene...

How the Company Makes Money

Kingworld Medicines Group Ltd. primarily makes money by selling pharmaceutical and healthcare products through wholesale/distribution and related sales activities. Key revenue streams typically include: (1) distribution/wholesale revenue from purchas...

Kingworld Medicines Group Ltd. Financial Statement Overview

Summary

Moderate financial profile marked by declining revenue, shrinking margins, rising debt-to-equity, and volatile cash flows, partially offset by stable equity and positive earnings.

Income Statement

45Neutral

Balance Sheet

55Neutral

Cash Flow

50Neutral

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	787.87M	917.34M	1.06B	1.08B	957.70M	847.39M
Gross Profit	240.04M	247.91M	270.45M	280.67M	277.63M	263.60M
EBITDA	80.78M	82.70M	110.77M	125.48M	118.07M	116.00M
Net Income	11.47M	11.28M	41.56M	38.10M	22.74M	30.32M
Balance Sheet
Total Assets	1.30B	1.44B	1.42B	1.34B	1.26B	1.21B
Cash, Cash Equivalents and Short-Term Investments	188.35M	274.70M	249.60M	194.03M	256.17M	198.41M
Total Debt	438.04M	434.05M	402.44M	354.43M	290.68M	238.96M
Total Liabilities	648.92M	753.86M	710.04M	638.30M	569.15M	493.19M
Stockholders Equity	596.45M	617.97M	639.79M	619.03M	615.58M	616.90M
Cash Flow
Free Cash Flow	-1.18M	54.92M	94.73M	-63.25M	93.64M	22.88M
Operating Cash Flow	38.39M	84.56M	135.82M	42.28M	186.55M	81.20M
Investing Cash Flow	-15.51M	-20.11M	-27.64M	-120.63M	-84.05M	-50.84M
Financing Cash Flow	-60.57M	-30.82M	-47.61M	4.37M	-51.31M	-87.20M

Kingworld Medicines Group Ltd. Technical Analysis

Technical Analysis SentimentNegative

Last Price0.38

Price Trends

50DMA0.39Negative

100DMA0.41Negative

200DMA0.45Negative

Market Momentum

MACD-0.00Negative

RSI47.75Neutral

STOCH62.50Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1110, the sentiment is Negative. The current price of 0.38 is below the 20-day moving average (MA) of 0.38, below the 50-day MA of 0.39, and below the 200-day MA of 0.45, indicating a bearish trend. The MACD of -0.00 indicates Negative momentum. The RSI at 47.75 is Neutral, neither overbought nor oversold. The STOCH value of 62.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1110.

Kingworld Medicines Group Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

HK:1110 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HK:0239	77Outperform	HKD 774.43M	7.76	13.59%	7.44%	10.63%	39.44%
HK:0897	59Neutral	HKD 401.18M	100.00	0.34%	―	-8.30%	-44.44%
HK:1110	56Neutral	HKD 227.44M	16.84	1.89%	8.45%	-13.82%	112.24%
HK:0858	54Neutral	HKD 147.90M	-0.13	-154.56%	―	-7.12%	-523.61%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
HK:0455	44Neutral	HKD 191.35M	-2.73	-14.55%	―	12.89%	-2.56%
HK:1498	42Neutral	HKD 123.04M	-4.04	-21.66%	―	-6.71%	43.14%

* Healthcare Sector Average

Performance Comparison

HK:1110 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
HK:1110	Kingworld Medicines Group Ltd.	0.38	-0.16	-29.25%
HK:0858	Extrawell Pharmaceutical Holdings Limited	0.05	-0.04	-44.57%
HK:0455	Tianda Pharmaceuticals Ltd.	0.09	-0.05	-34.07%
HK:0897	Wai Yuen Tong Medicine Holdings Limited	0.36	-0.10	-21.74%
HK:1498	PuraPharm Corp. Ltd.	0.23	-0.19	-45.24%
HK:0239	Pak Fah Yeow International Limited	2.48	0.25	11.09%

Kingworld Medicines Group Ltd. Corporate Events

Kingworld Medicines Narrows Shareholder Loss Despite Sharp Revenue Decline

Aug 27, 2026

Kingworld Medicines Group Ltd., a pharmaceutical and healthcare products distributor in mainland China with supplementary income from investment properties and equity interests, reported mixed interim results for the six months ended 30 June 2026. Th...

Kingworld Medicines Schedules Board Meeting to Review Interim Results and Dividend

Aug 14, 2026

Kingworld Medicines Group Ltd. has announced that its board of directors will convene on 27 August 2026 in Hong Kong to review and approve the unaudited interim results for the six months ended 30 June 2026. The meeting will also consider the recomme...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 15, 2026

Kingworld Medicines Group Ltd. AI Stock Analysis